Roche Holding AG (OTCMKTS:RHHBY – Get Free Report) shares reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $44.31 and last traded at $44.24, with a volume of 7251897 shares changing hands. The stock had previously closed at $43.26.
Wall Street Analyst Weigh In
Several research firms have issued reports on RHHBY. Morgan Stanley began coverage on shares of Roche in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Sanford C. Bernstein raised shares of Roche to a “strong-buy” rating in a report on Thursday, January 30th. Finally, UBS Group raised shares of Roche from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy”.
View Our Latest Stock Analysis on RHHBY
Roche Stock Up 2.3 %
Institutional Investors Weigh In On Roche
A number of hedge funds have recently modified their holdings of RHHBY. Brooklyn Investment Group acquired a new stake in shares of Roche in the third quarter valued at about $40,000. IHT Wealth Management LLC acquired a new stake in Roche during the third quarter worth about $236,000. Verity Asset Management Inc. increased its position in Roche by 26.8% during the fourth quarter. Verity Asset Management Inc. now owns 8,036 shares of the company’s stock worth $280,000 after purchasing an additional 1,697 shares during the last quarter. Canopy Partners LLC increased its position in Roche by 4.6% during the third quarter. Canopy Partners LLC now owns 7,772 shares of the company’s stock worth $310,000 after purchasing an additional 344 shares during the last quarter. Finally, HighPoint Advisor Group LLC increased its position in Roche by 2.8% during the fourth quarter. HighPoint Advisor Group LLC now owns 11,091 shares of the company’s stock worth $387,000 after purchasing an additional 304 shares during the last quarter.
About Roche
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
Recommended Stories
- Five stocks we like better than Roche
- Why Invest in High-Yield Dividend Stocks?
- Can TikTok Stock Picks Really Make You Rich?
- How to Invest in the FAANG Stocks
- The “Quality” Rotation: Back to Basics Investing
- What is the NASDAQ Stock Exchange?
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.